We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Authorized Generic Deals Are ‘Pay for Delay,’ FTC Tells Courts … Again
Authorized Generic Deals Are ‘Pay for Delay,’ FTC Tells Courts … Again
October 23, 2012
The FTC is challenging a GlaxoSmithKline (GSK)-Teva patent settlement deal, filing an amicus brief that argues authorized generic agreements fall under the category of pay-for-delay deals and are anticompetitive.